Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · IEX Real-Time Price · USD
19.78
+0.26 (1.33%)
Jun 18, 2024, 4:00 PM EDT - Market closed

Company Description

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.

The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.

Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.

The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA.

It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients.

The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016.

Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Fulgent Genetics, Inc.
Fulgent Genetics logo
Country United States
Founded 2011
IPO Date Sep 29, 2016
Industry Diagnostics & Research
Sector Healthcare
Employees 1,184
CEO Ming Hsieh

Contact Details

Address:
4399 Santa Anita Ave
El Monte, California 91731
United States
Phone 626-350-0537
Website fulgentgenetics.com

Stock Details

Ticker Symbol FLGT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001674930
CUSIP Number 359664109
ISIN Number US3596641098
Employer ID 81-2621304
SIC Code 8071

Key Executives

Name Position
Ming Hsieh Chairman and Chief Executive Officer
Jian Xie Chief Operating Officer and President
Paul Kim Chief Financial Officer
Dr. Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D. Chief Scientific Officer and Laboratory Director
Natalie Prescott General Counsel and Chief Privacy Officer
Doreen Ng Vice President of Operations and Compliance and GM of Houston Office
Jakub Sram Vice President of Business Development and Sales
Ellen Tsui Vice President of Human Resources
Brandon Perthuis Chief Commercial Officer
Dr. Lawrence M. Weiss M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
May 16, 2024 8-K Current Report
May 3, 2024 10-Q Quarterly Report
May 3, 2024 8-K Current Report
Mar 27, 2024 ARS Filing
Mar 27, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 27, 2024 DEF 14A Other definitive proxy statements
Feb 28, 2024 10-K Annual Report
Feb 28, 2024 8-K Current Report
Feb 8, 2024 UPLOAD Filing
Jan 30, 2024 UPLOAD Filing